Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2008

01-05-2008 | Poster presentation

Adherence to hormone therapy in a chemoprevention randomised trial

Authors: L Atkins, V Jenkins, L Fallowfield, A Howell

Published in: Breast Cancer Research | Special Issue 2/2008

Login to get access

Excerpt

Nonadherence to oral medication exists amongst women with breast cancer [1] and those participating in randomised clinical trials [2]. There is also evidence to suggest that nonadherence is more prevalent in chemoprevention trials than in adjuvant trials, with between 20% and 46% of patients in chemoprevention trials not adhering to medication [3]. The purpose of this study is to examine adherence amongst a subgroup of women participating in the International Breast Cancer Intervention Study (IBIS II) cognitive subprotocol. IBIS II is a randomised double-blind chemoprevention clinical trial of anastrozole versus placebo in postmenopausal women at high risk of breast cancer. …
Literature
1.
Atkins L, Fallowfield L: Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006, 42: 2271-2276. 10.1016/j.ejca.2006.03.004.CrossRefPubMed
2.
Fallowfield L, Fleissig A, Edwards R, et al: Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol. 2001, 19: 1885-1892.PubMed
3.
Chlebowski RT, Geller ML: Adherence to endocrine therapy for breast cancer. Oncology. 2006, 71: 1-9.PubMed
Metadata
Title
Adherence to hormone therapy in a chemoprevention randomised trial
Authors
L Atkins
V Jenkins
L Fallowfield
A Howell
Publication date
01-05-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1940

Other articles of this Special Issue 2/2008

Breast Cancer Research 2/2008 Go to the issue

Poster presentation

Quantitative proteomics reveals proteins associated with radiotherapy resistance in breast cancer cells

Lecture presentation

Molecular diversity of human breast cancer: clinical and therapeutic implications

Oral presentation

Use of BRCA1 protein:protein interactions to classify cancer risk

Poster presentation

Proteomic screening of 725 antibodies simultaneously using antibody microarray technology to identify proteins associated with radiotherapy resistance in breast cancer cells

Poster presentation

Exploring the acceptability of, and preferences for, an ongoing support network for known BRCA1 and BRCA2 mutation carriers

Poster presentation

Insulin-like growth factor binding protein 3 modulates epidermal growth factor (EGF)-induced growth of breast epithelial cells by altering EGF receptor internalization
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits